Dimerix Ltd (ASX:DXB) CEO Nina Webster updates Proactive’s Elisha Newell on the company’s mission to meet unmet medical need ahead of the Peak Asset Management Microcap Conference on Thursday, July 13. Dimerix is using innovative receptor technology to uncover pharmaceutical products that will improve patient’s lives, and Webster says the company’s core focus is bringing its flagship DMX-200 candidate through Phase 3 clinical trials. Investors can register to attend the Peak Asset Management conference in Melbourne here.
Dimerix talks Phase 3 clinical trial ahead of Peak Asset Management conference
